Sunday, July 12, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitors”

2,466 pharma patents match "inhibitors" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,466
Index total 30,257
Page 36 / 103

Quick answer

This filtered view shows 2,466 pharmaceutical patents matching "inhibitors" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,466 results for “inhibitors” · 30,257 patents in full index Clear search

  1. US 10451610

    Prediction of response to PARP inhibitors and combinational therapy targeting C-MET and PARP1

    The Board of Regents of the University of Texas System · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted
  2. US 10450285

    2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors

    University College Cardiff Consultants Limited · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted
  3. US 10448637

    Inhibitors of GRB2-associated binding protein 1 (GAB1) and methods of treating cancer using the same

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted
  4. US 10449182

    Sorafenib derivatives as p21 inhibitors

    The Regents of the University of California · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted
  5. US 10450572

    Androgen receptor variant inhibitors and methods of using

    Regents of the University of Minnesota · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted
  6. US 10441586

    CRMP2 SUMOylation inhibitors and uses thereof

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Oct 15, 2019 · Expires Oct 10, 2039

    granted
  7. US 10442791

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Oct 15, 2019 · Expires Oct 10, 2039

    granted
  8. US 10434096

    Tyrosine kinase inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted
  9. US 10434100

    Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes

    Lixte Biotechnology, Inc. · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted
  10. US 10435355

    Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability and their use as medicaments

    The Regents of the University of California · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted
  11. US 10428057

    Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease

    The Board of Regents of the University of Texas System · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted
  12. US 10428050

    Substituted reverse pyrimidine Bmi-1 inhibitors

    PTC THERAPEUTICS, INC. · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted
  13. US 10428157

    Dosing regimens for use with PCSK9 inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted
  14. US 10428028

    HDAC inhibitors

    BIOMARIN PHARMACEUTICAL INC. · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted
  15. US 10426767

    Methods of treating cancer with farnesyltransferase inhibitors

    Kura Oncolofy, Inc. · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted
  16. US 10421765

    Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase

    The Board of Regents of the University of Texas System · Granted Sep 24, 2019 · Expires Sep 19, 2039

    granted
  17. US 10420813

    Competitive inhibitors of invariant chain expression and/or ectopic clip binding

    The Regents of the University of Colorado, a Body Corporate · Granted Sep 24, 2019 · Expires Sep 19, 2039

    granted
  18. US 10420758

    Indolinyl-sulfonamide inhibitors of tankyrase and methods of use thereof

    The Board of Regents of the University of Texas System · Granted Sep 24, 2019 · Expires Sep 19, 2039

    granted
  19. US 10414740

    Glutaminase inhibitors and method of use

    Agios Pharmaceuticals, Inc. · Granted Sep 17, 2019 · Expires Sep 12, 2039

    granted
  20. US 10407409

    6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD

    Takeda Pharmaceutical Company Limited · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted
  21. US 10407445

    Hepatitis C virus inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted
  22. US 10398706

    Heteroaryldiazepine derivatives as RSV inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Sep 3, 2019 · Expires Aug 29, 2039

    granted
  23. US 10400010

    Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics

    The Regents of the University of California · Granted Sep 3, 2019 · Expires Aug 29, 2039

    granted
  24. US 10392376

    Heterocyclic inhibitors of ATR kinase

    The Board of Regents of the University of Texas System · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted